2-chloro-5-(2-dimethylamino-phenylthio)-4-nitroaniline | 606937-79-5

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-chloro-5-(2-dimethylamino-phenylthio)-4-nitroaniline
• 英文别名: 2-chloro-5-(2-dimethylaminomethyl-phenylthio)-4-nitroaniline；2-Chloro-5-[2-[(dimethylamino)methyl]phenyl]sulfanyl-4-nitroaniline
• CAS: 606937-79-5
• 化学式: C₁₅H₁₆ClN₃O₂S
• 分子量: 337.83
• InChiKey: HHDLJUCXMKJQLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Fluorinated phenyl thiophenyl derivatives and their use for imaging serotonin transporters
  申请人：——

  公开号：US20030236234A1

  公开（公告）日：2003-12-25

  This invention relates to novel fluorinated phenyl thiphenyl (also named diarylsulfide) derivatives and their use in Positron Emission Tomagraphy (PET) imaging of Serotonin Transporters (SERTS). The present invention also provides diagnostic compositions comprising the novel compounds of the present invention, and a pharmaceutically acceptable carrier or diluent. The invention further provides a method of imaging SERTS, comprising introducing into a patient a detectable quantity of a labeled compound of the present invetion, or a pharmaceutically acceptable salt, ester, amide or prodrug thereof.

  本发明涉及一种新型的氟化苯基噻吩（也称二芳基硫醚）衍生物及其在正电子发射断层扫描（PET）成像中用于血清素转运体（SERTS）的应用。本发明还提供了包含本发明新化合物的诊断组合物，并且还包括药学上可接受的载体或稀释剂。本发明还提供了一种成像SERTS的方法，包括向患者引入本发明标记化合物的可检测量，或其药学上可接受的盐、酯、酰胺或前药。
• US7041851B2
  申请人：——

  公开号：US7041851B2

  公开（公告）日：2006-05-09
• [EN] FLUORINATED PHENYL THIOPHENYL DERIVATIVES AND THEIR USE FOR IMAGING SEROTONIN TRANSPORTERS<br/>[FR] DERIVES FLUORES DE PHENYL THIOPHENYL ET LEUR UTILISATION DANS L'IMAGERIE DE TRANSPORTEURS DE LA SEROTONINE
  申请人：KUNG HANK F

  公开号：WO2003078393A2

  公开（公告）日：2003-09-25

  This invention relates to novel fluorinated phenyl thiphenyl (also named diarylsulfide) derivatives and their use in Positron Emission Tomagraphy (PET) imaging of Serotonin Transporters (SERTS). The present invention also provides diagnostic compositions comprising the novel compounds of the present invention, and a pharmaceutically acceptable carrier or diluent. The invention further provides a method of imaging SERTS, comprising introducing into a patient a detectable quantity of a labeled compound of the present invention, or a pharmaceutically acceptable salt, ester, amide or prodrug thereof.